SYNE3 and invasive breast carcinoma: Meanwhile, according to GEPIA database, SYNE3 was significantly expressed less in 9 cancer types, including invasive breast carcinoma (BRCA), lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC)(P < 0.0001), which were consistent with our IHC results in these tumors.